UPDATE: Raymond James Initiates Coverage on Accretive Health with Strong Buy Rating, $16 PT
In a report published Wednesday, Raymond James initiated coverage on Accretive Health (NYSE: AH) with a Strong Buy rating and $16.00 price target.
Raymond James noted, “We initiate coverage of Accretive Health with a Strong Buy rating and $16 price target. Our rating considers what we believe are the four most important components to the Accretive Health story: 1) 2013 healthcare information technology (HIT) focus to shift to revenue cycle; 2) differentiated infused management model; 3) opportunity to drive meaningful margin expansion; and 4) multiple expansion expected with Minnesota litigation in the rearview mirror. We view Accretive as a mid-teens to low-20 percentage point revenue growth story with non-GAAP EPS and adj. EBITDA growing at a faster pace as margins expand.”
Accretive Health closed on Tuesday at $12.47.
Latest Ratings for AH
|Sep 2013||Credit Suisse||Downgrades||Outperform||Neutral|
|Feb 2013||Dougherty & Company||Downgrades||Buy||Neutral|
|Jan 2013||Raymond James||Initiates Coverage on||Strong Buy|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.